The weakest nicotine pouches you can actually buy

The weakest nicotine pouch you can actually buy depends on where you are: in the United States it is on! at 2 mg, the lowest strength FDA has authorised; in the UK it is ZYN’s Mini X-Low at 1.5 mg. In Sweden, several brands sell a “lowest” strength that carries no number at all — just dots, or the word Medium. And a declared milligram figure is a far weaker guide than it looks: how long you keep the pouch in moves the dose you absorb more than the label does.

The lowest strengths genuinely on sale

Every figure below is the manufacturer’s own, or the regulator’s. Where a maker publishes nothing, I have said so rather than borrowing a retailer’s number.

Market	Lowest on sale	Unit the maker uses	Pouch mass published?
US (FDA-authorised)	on! 2 mg — three flavours	mg per pouch	No
US (ZYN)	ZYN 3 mg	mg per pouch	Yes — 0.4 g
UK	ZYN Mini X-Low 1.5 mg — three flavours, 10 per can	mg per pouch	No
UK (VELO)	VELO Mellow 4 mg	mg per pouch, plus dots	No
UK (Nordic Spirit)	Mellow 4 mg	mg per pouch, plus dots	No
Denmark, Czechia (VELO)	4 mg	mg per pouch	No
Sweden (VELO)	6 mg	mg per pouch	No
Sweden (Zone, X All White, Skruf SUPERWHITE)	Unknowable	Dots, or the words Medium / Strong	No
EU (LOOP)	6.3 mg per pouch	mg per pouch and per can, plus dots	No

Two entries there need qualifying, because both are commonly got wrong.

“Mini” does not mean weak. VELO sells 6 mg in both Slim and Mini cans, and describes the Mini as “way smaller” — the same declared milligrams in a smaller pouch, which is a higher concentration, not a lower dose. LOOP is worse: its lowest product is the Smooth Mint Mini at “Nicotine/pouch: 6,3 mg”, and a LOOP Mini Hyper is 10.5 mg. If you have been treating “mini” as the beginner’s option, it is a size, not a strength.

The 1.5 mg ZYN is real, and ZYN’s own site denies it three times over. The UK product pages sell “ZYN Spearmint Mini X-Low 1.5mg” and two stablemates, described as “designed for existing nicotine users who are new to nicotine pouches”. Meanwhile ZYN’s own UK strengths chart lists only 3 mg upward; its Mini category page carries a 1.5 mg filter and the three X-Low products, then answers its own FAQ with “ZYN Mini Pouches are available in Low (3mg) and Medium (6mg) nicotine levels”; and the can count conflicts too — the X-Low rows say ten per can, the FAQ says twenty. One company, one country, three contradictions about whether its weakest product exists.

The brands that publish no number at all

This is the part of the low end nobody quantifies, and it is not a fringe case. On Imperial Brands’ own Swedish sites, Zone renders every product as a bare dot count — “Cool Mint / 1 2 3 4 5 6 7” — with no milligram figure anywhere on the page. X All White uses words only: Medium, Strong, Extra Strong. Skruf’s SUPERWHITE brand page says the range “kommer i olika format och styrkor” and then lists no strengths at all.

The German regulator found exactly this across the market: nicotine content “was declared clearly on only about a third of the nicotine pouches examined”, with the rest using “either a scale (such as a strength of ‘3 out of 5’) for which no further details were given or figurative language” — BfR’s examples being “‘easy’, ‘medium’, ‘strong’, ‘extra strong’, ‘ultra’, ‘extreme’, ‘danger strong’ or ‘brutal'”.

So for two-thirds of the market, the question “which is weakest” has no answer the manufacturer is willing to give. And one more thing worth watching: X All White is currently flagging all four of its Medium products as “Utgår” — being discontinued — leaving a catalogue of Strong and Extra Strong. The low end of that range is being pruned.

“Weakest” by which measurement?

Three different quantities get called strength, and rankings mix them silently:

Declared content — what the maker prints on the can.
Measured content — what a laboratory extracted from the pouch.
Delivered nicotine — what actually reached the bloodstream.

At the low end these diverge more, not less, because the absolute numbers are small enough that ordinary manufacturing variation swamps the difference between tiers.

RIVM’s laboratory tested eleven products against their labels. Its lowest-declared product — 4.0 mg/g, 1.6 mg per pouch — measured at 2.7 mg/g, an agreement of 67%, the joint-worst in the table. Multiply by the measured pouch weight and that pouch held about 1.11 mg, which is below the 1.79 mg that BfR reports as the lowest content it found in 44 German-market products. But the pattern is not uniform: another low-end product in the same table, declared 3.0 mg in a 400 mg pouch, came back at 89% — among the best agreements RIVM recorded. The honest statement is that the low end carries the widest spread, not a consistent shortfall.

RIVM volunteers two caveats that matter here. Its method was not validated — “De nicotinegehaltes zijn gescreend middels een niet-gevalideerde methode” — and, more pointed for weak pouches, “Binnen de verpakking van één merk zit er gemiddeld een marge van 18% in gewicht van de zakjes.” An 18% within-can spread in pouch weight is, on a 1.5 mg or 2 mg pouch, a bigger absolute swing than the gap between consecutive tiers at the bottom of a range.

The one independent, non-industry measurement at the low end comes from the BfR-funded team of Mallock-Ohnesorg and colleagues, who found a pouch declared at 6 mg analysed at 4.8 mg — 80% of label — and noted it released only 38% of what it contained.

Does a weak pouch actually deliver less?

Less than a strong one, yes. Less than you would guess from the number on the can, often not — and a regulator says why, plainly.

RIVM: “een langer gebruik van een nicotinezakje met een laag nicotinegehalte kan leiden tot eenzelfde opgenomen dosis nicotine als een korter gebruik van een nicotinezakje met een hoger nicotinegehalte” — longer use of a low-nicotine pouch can lead to the same absorbed dose as shorter use of a stronger one. Duration is a dial, and it is in your mouth, not on the label.

RIVM goes further, and this is the sourced reason a weak pouch may still be meaningfully different at equal dose: reaching the same total faster produces “hogere plasma nicotineconcentraties … en een groter effect op de hartslag en bloeddruk” — higher peaks and a bigger effect on heart rate and blood pressure. Same dose, slower, means a lower peak.

The concrete numbers at the bottom of the range are more sobering than the marketing suggests:

A 3 mg pouch held one hour releases about 1.6 mg and reaches a peak plasma concentration RIVM gives as 8 ng/mL — which it describes as comparable to smoking one cigarette per hour.
Pouches of 3.30 to 3.82 mg, held 30 minutes, reached peak concentrations “from 9.0 to 11.5 ng/ml … and were 16.3 ng/ml for the cigarettes” in a manufacturer study BfR summarises. That is a roughly 3.5 mg pouch landing at 56–71% of a cigarette’s peak.
A 4 mg pouch against a 4 mg medicine, in another manufacturer study: “The peak concentrations (Cmax) were 8.5 ng/ml for the nicotine pouch, 4.4 ng/ml for the chewing gum and 8.3 ng/ml for the lozenges.” At identical declared milligrams, the pouch and the FDA-approved lozenge are indistinguishable, and both roughly double the gum.

Both pouch studies above are manufacturer-funded; I am quoting them through BfR’s own summaries, which is where I would rather take them from. The direction they point in is not controversial, though: a pouch at the bottom of the range is not a trivial dose, and the weakest thing you can buy still lands in the same order of magnitude as a cigarette’s peak if you keep it in long enough.

One result deserves its own line, from the independent BfR-funded trial: a nicotine-free pouch reduced cigarette craving, which the authors attribute to sensory cues and expectation rather than nicotine. Which means how satisfied you feel in the first ten minutes is not a measurement of dose, and should not be how you choose a strength.

Milligrams per pouch, milligrams per gram, and the missing weights

A per-pouch figure tells you the load; a per-gram figure tells you the concentration. You cannot convert between them without the pouch’s mass — and across this entire exercise, exactly one manufacturer published one. ZYN’s US FAQ: “One ZYN pouch weighs approximately 0.4 grams.”

So: ZYN 3 mg is 7.5 mg/g, ZYN 6 mg is 15.0 mg/g, and ZYN ULTRA’s 11 mg in a 0.8 g pouch is 13.75 mg/g — the strongest pouch FDA has authorised is, per gram, weaker than the ordinary one. All three are my arithmetic from ZYN’s own mass. For every other product in the table above, the conversion simply cannot be done: on!, VELO, Nordic Spirit, LOOP, Zone, X All White, Skruf and ZYN’s own UK site publish no pouch weight at all. FDA’s public review of the on! authorisations contains no mass and no concentration either.

RIVM’s table shows what that hides. Two products both declared 3.0 mg per pouch: one in a 320 mg pouch at 9.4 mg/g, the other in a 400 mg pouch at 7.5 mg/g. Identical labels, 25% apart in concentration.

What the law does at the low end

No market anywhere sets a minimum strength. Several set maximums, and they are written in incompatible units, which is where the low end gets interesting:

Latvia: four milligrams per gram — a per-gram cap. On the only manufacturer-published mass in existence, ZYN 3 mg at 7.5 mg/g fails it by nearly two-fold. ZYN’s UK 1.5 mg Mini would pass at 0.4 g and fail at 0.3 g, and since no mass is published, nobody outside the company can say which. A per-gram cap is, in practice, enforceable only against the one company that tells you what its pouches weigh.
Denmark: 9.0 mg per pouch. Every product in the table above clears it comfortably.
Czechia: 12 mg per dose and 240 mg per can. A can of 2 mg on! is nowhere near either.
The Netherlands set the lowest threshold ever written, then gave up on it. BfR records that “In the Netherlands, nicotine pouches containing 0.035 mg or more of nicotine have been banned since 9 November 2021” — a ceiling so low that only a functionally nicotine-free pouch was ever lawful. The Dutch health ministry’s own 2024 memo states that threshold twice as “0,035 mg” and once as “0,035 gram”, a thousand-fold discrepancy inside one government document. The ministry then explained why it moved to an outright ban: it “wordt het handhaven voor de NVWA vergemakkelijkt omdat zij niet hoeven aan te tonen hoeveel mg nicotine er in een nicotinezakje zit” — an outright ban spares the regulator from having to prove how many milligrams are in the pouch. The measurement problem was itself the reason to stop measuring.

Who a weak pouch is actually for — and what nobody tells you

Manufacturers do publish beginner guidance. VELO’s is the most directive: “We recommend that new users start on our lower strength Mini range”, and on its strongest tier, “Experienced nicotine users that are new to VELO should still start with Mellow.” Nordic Spirit sorts users into “NEW USER / 1 or 2 dots on the can … For existing adult smokers or vapers who are new to nicotine pouches.”

But notice what none of it is keyed to. It sorts you by your prior experience with pouches, not by how dependent on nicotine you are. Nordic Spirit’s guidance is expressed entirely in dots, never in milligrams, on a page that never shows the milligrams — and its dot scale runs to six while the brand sells three strengths.

Set that against a regulated medicine. An FDA-approved nicotine lozenge label carries a real rule, keyed to an observable fact about the user: “if you smoke your first cigarette within 30 minutes of waking up, use 4 mg nicotine lozenge”; “if you smoke your first cigarette more than 30 minutes after waking up, use 2 mg nicotine lozenge”, with a twelve-week taper schedule and a minimum daily count. No pouch sold anywhere carries anything like it.

And the sting in the tail: per-pouch weakness is not daily weakness. BfR’s survey data on German users records that the most popular consumption was ten to twenty pouches a day. At that rate, a 2 mg pouch is 20–40 mg of declared nicotine daily — more than a single can’s strongest product, and above the per-pouch ceiling BfR itself recommends. If you step down a tier and double the number you get through, you have not stepped down.

Common questions

Is there anything weaker than 1.5 mg? Not as a nicotine pouch, from any manufacturer I could verify. Below that, the category is nicotine-free pouches, which are a different product.

Is a weak pouch a good way to quit? No pouch is a cessation product, and none is authorised as one. Stopping nicotine entirely is the lowest-risk course.

Is the weakest pouch the mildest-feeling one? Not reliably. pH drives the free-base fraction — the share of nicotine that can cross the mucosa — and across 37 brands the CDC found a pH range of 6.94 to 10.1, which BfR converts to free-base proportions “of 7.7% to 99.2%”. That thirteen-fold swing is larger than the entire declared-strength range at the low end, and no manufacturer publishes a pH value.

Why do two “3 mg” pouches feel different? Different pouch mass, different pH, different fleece, different dwell time. The milligram figure is one of five variables and the only one printed.

Sources

FDA, Nicotine Pouch Products Authorized by the FDA — content current as of 21 August 2026; the three 2 mg on! entries are the lowest authorised US strength.
Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches — market analysis, declaration practice, pH and free-base range, and summaries of the manufacturer pharmacokinetic studies.
RIVM, Nicotinezakjes, briefrapport 2020-0152 — Table B4.1 declared-versus-measured data, the duration principle, and the ZYN 3 mg figures.
Mallock-Ohnesorg N. et al., Small pouches, but high nicotine doses, Frontiers in Pharmacology 15 (2024) — funded by BfR; authors declare no commercial relationships.
Ministerie van Volksgezondheid, Welzijn en Sport, nota of 5 March 2024 — the 0.035 mg threshold and the enforcement rationale.
Swedish Match North America, ZYN US FAQ — the only manufacturer-published pouch mass found.
ZYN UK, X-Low 1.5 mg range and strengths guide.
VELO UK, low-strength range and product strengths.
Nordic Spirit, Your Nordic Guide.
US National Library of Medicine, DailyMed label, nicotine polacrilex lozenge 2 mg and 4 mg.

Last verified: 14 October 2026.